[Novelties in the treatment of heart failure].

Abstract

Heart failure (HF) is a complex clinical syndrome which is manifested by characteristic symptoms and objective signs of cardiac insufficiency. The incidence of HF, particularly its chronic form, is estimated 0.4-2 % in the central and western Europe, with an increase in higher age groups, affecting 10-20 % of the population aged over 80. With respect to its growing incidence and prevalence, novel modalities of pharmacological and non-pharmacological treatment are being developed in order to improve quality of life and survival of the affected patients. This review based on up-to-date guidelines focuses in the first part on brief description of the possibilities of diagnosing heart failure, including the novelties arising out from the latest clinical and preclinical studies (such as soluble ST2, FSTL1, etc), further it concentrates on innovations in pharmacological treatment of chronic (ivabradine, ARNI, gliflozins) and acute (ularitide, serelaxin, nesiritide) HF. The last part provides an overview of available non-pharmacological HF therapeutics options (modulation of cardiac contraction, influencing the activity of sympathetic and parasympathetic nervous systems and permanent and temporary device support).Key words: ARNI - ECMO - gliflozins - heart failure - modulation of sympathetic and parasympathetic nervous systems - sacubitril-valsartan - therapy.

• Authors: Filip Souček, Jan Novak
• Journal: Vnitrni lekarstvi (Vnitr Lek) Spring 2017 Vol. 63 Issue 4 Pg. 255-264 ISSN: 0042-773X [Print] Czech Republic
• Vernacular Title: Novinky v léčbě srdečního selhání.
• PMID: 28520449 (Publication Type: Journal Article, Review)

Chemical References

• Aminobutyrates
• Angiotensin Receptor Antagonists
• Benzazepines
• Biphenyl Compounds
• Cardiovascular Agents
• Diuretics
• Drug Combinations
• Follistatin-Related Proteins
• IL1RL1 protein, human
• Interleukin-1 Receptor-Like 1 Protein
• Natriuretic Agents
• Peptide Fragments
• Recombinant Proteins
• Tetrazoles
• serelaxin protein, human
• Natriuretic Peptide, Brain
• FSTL1 protein, human
• Ivabradine
• Ularitide
• Valsartan
• Atrial Natriuretic Factor
• Relaxin
• sacubitril and valsartan sodium hydrate drug combination

Topics

• Acute Disease
• Aminobutyrates (therapeutic use)
• Angiotensin Receptor Antagonists (therapeutic use)
• Atrial Natriuretic Factor (therapeutic use)
• Benzazepines (therapeutic use)
• Biphenyl Compounds
• Cardiovascular Agents (therapeutic use)
• Chronic Disease
• Diuretics (therapeutic use)
• Drug Combinations
• Europe
• Follistatin-Related Proteins (blood)
• Heart Failure (blood, diagnosis, drug therapy)
• Humans
• Interleukin-1 Receptor-Like 1 Protein (blood)
• Ivabradine
• Natriuretic Agents (therapeutic use)
• Natriuretic Peptide, Brain (therapeutic use)
• Peptide Fragments (therapeutic use)
• Quality of Life
• Recombinant Proteins (therapeutic use)
• Relaxin (therapeutic use)
• Tetrazoles (therapeutic use)
• Valsartan